KR900700124A - 흑색종 치료용 il-2 및 dtic의 치료 조성물 - Google Patents
흑색종 치료용 il-2 및 dtic의 치료 조성물Info
- Publication number
- KR900700124A KR900700124A KR1019890702190A KR890702190A KR900700124A KR 900700124 A KR900700124 A KR 900700124A KR 1019890702190 A KR1019890702190 A KR 1019890702190A KR 890702190 A KR890702190 A KR 890702190A KR 900700124 A KR900700124 A KR 900700124A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- dtic
- ala
- mutein
- des
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010002350 Interleukin-2 Proteins 0.000 title claims 23
- 239000000203 mixture Substances 0.000 title claims 16
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 title claims 9
- 230000001225 therapeutic effect Effects 0.000 title claims 4
- 201000001441 melanoma Diseases 0.000 title claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 229920001519 homopolymer Polymers 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 1
- 229920000037 Polyproline Polymers 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 108010026466 polyproline Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (17)
- 사람의 흑색종 치료에 유용한 조성물을 제조하기 위한 상승적 유효량의 IL-2 및 DTIC의 용도.
- 제1항에 있어서, IL-2가 실질적으로 천연 포유류 IL-2의 아미노산 서열을 갖는 조성물.
- 제1항에 있어서, IL-2 및 DTIC가 정맥 주입에 의한 비경구 투여용을 제형화된 조성물.
- 제3항에 있어서, DTIC의 투여가 IL-2의 투여에 선행하는 조성물.
- 제3항에 있어서, IL-2투여가 DTIC의 투여에 선행하는 조성물.
- 제3항에 있어서, IL-2 및 DTIC가 동시에 투여되는 조성물.
- 제3항, 제4항, 제5항 및 제6항 중의 어느 한 항에 있어서, IL-2의 투여량이 1주당 약5내지 10㎎/㎡이고 DTIC의 투여량이 1주당 약 750내지 1300㎎/㎡인 조성물.
- 제4항, 제5항 및 제6항 중의 어느 한항에 있어서, 연속적인 치료학적 주기당 IL-2의 증가 용량을 투여하는 조성물.
- 제5항에 있어서, IL-2를 1주당 약 5내지 10㎎/㎡으로 정맥 주입시켜 투여하고, 치료학적 주기의 2주를 반복한 다음, DTIC를 약 1.0g/㎡으로 치료학적 주기의 3주 동안 정맥 주입시켜 투여하는 조성물.
- 제6항에 있어서, DTIC를 약 200내지 250㎎/㎡/일로 5일 동안, IL-2를 약 0.5내지 2㎎/㎡/일로 5일동안 정맥 주입시켜 투여하고, 계속해서 치료학적 주기의 2주를 반복하는 조성물.
- 제2항에 있어서, IL-2가 실질적으로 천연 사람 IL-2의 아미노산 서열을 갖고, 재조합 DNA기술로 생산되는 조성물.
- 제11항에 있어서, IL-2가 뮤테인인 조성물.
- 제12항에 있어서, 뮤테인이, 단독으로 또는 혼합하여, 완전한 천연 사람 서열에 따라 번호를 붙인 125위치에서 세린 또는 알라닌 잔기를 갖고, 1위치에는 알라닌 잔기가 없으며, 104위치에서 세린 또는 알라닌 잔기를 갖는 조성물.
- 제12항 또는 제13항에 있어서, 뮤테인이 des-ala, IL-2, des-ala1ala104IL-2, des-ala1ala104ser125IL-2, des-ala1ser125IL-2, ala104IL-2, ser125IL-2, 또는 ala104ser125IL-2인 조성물.
- 제14항에 있어서, 뮤테인이 des-ala1ser125IL-2인 조성물.
- 제1항에 있어서, IL-2가 이의 용해도 및 순환 반감기를 증가시키기 위해 화학적으로 변형된 조성물.
- 제16항에 있어서, IL-2가 폴리에틸렌 글리콜의 단독 중합체, 폴리프롤린, 헤파린 단면 또는 풀릴옥시에틸화폴리올(여기서, 폴리에틸렌 글리콜 단독중합체는 비치한 되거나 한쪽 말단이 알킬 그룹에 의해 치환될 수 있다)에 공유결합되어 있는 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/174,000 US4999339A (en) | 1988-03-28 | 1988-03-28 | Combination therapy of IL-2 and DTIC for the treatment of melanoma |
| US174,000 | 1988-03-28 | ||
| PCT/US1989/001236 WO1989009062A1 (en) | 1988-03-28 | 1989-03-24 | Combination therapy of il-2 and dtic for the treatment of melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR900700124A true KR900700124A (ko) | 1990-08-11 |
Family
ID=22634400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019890702190A Withdrawn KR900700124A (ko) | 1988-03-28 | 1989-03-24 | 흑색종 치료용 il-2 및 dtic의 치료 조성물 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4999339A (ko) |
| EP (1) | EP0422010A1 (ko) |
| JP (1) | JPH03503647A (ko) |
| KR (1) | KR900700124A (ko) |
| AU (1) | AU3427389A (ko) |
| IL (1) | IL89750A0 (ko) |
| WO (1) | WO1989009062A1 (ko) |
| ZA (1) | ZA892275B (ko) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5229109A (en) * | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| WO2001077137A1 (en) * | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1401477A4 (en) * | 2001-05-25 | 2005-02-02 | Human Genome Sciences | CHIMIOKINE BETA-1 HYBRID PROTEINS |
| CA2484556A1 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2277889B1 (en) * | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
| EP1594530A4 (en) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | HYBRID PROTEINS OF ALBUMIN |
| CA2558667A1 (en) * | 2004-02-27 | 2005-09-15 | Antisense Pharma Gmbh | Antisense oligonucleotides for inhibiting the formation of metastases in cancer |
| US20080227762A1 (en) * | 2004-03-02 | 2008-09-18 | Wisconsin Alumni Research Foundation | Lupeol anti-tumor agent and uses thereof |
| WO2013177187A2 (en) * | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| MX2019014023A (es) | 2017-05-24 | 2020-02-17 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| BE1001901A3 (fr) * | 1986-04-24 | 1990-04-10 | Cetus Corp | Composition a utiliser en therapie combinee au moyen d'interleukine-2 et de glucocorticoides. |
-
1988
- 1988-03-28 US US07/174,000 patent/US4999339A/en not_active Expired - Lifetime
-
1989
- 1989-03-24 EP EP89904884A patent/EP0422010A1/en not_active Withdrawn
- 1989-03-24 WO PCT/US1989/001236 patent/WO1989009062A1/en not_active Ceased
- 1989-03-24 KR KR1019890702190A patent/KR900700124A/ko not_active Withdrawn
- 1989-03-24 JP JP1504714A patent/JPH03503647A/ja active Pending
- 1989-03-24 AU AU34273/89A patent/AU3427389A/en not_active Abandoned
- 1989-03-27 IL IL89750A patent/IL89750A0/xx unknown
- 1989-03-28 ZA ZA892275A patent/ZA892275B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU3427389A (en) | 1989-10-16 |
| ZA892275B (en) | 1990-11-28 |
| IL89750A0 (en) | 1989-09-28 |
| WO1989009062A1 (en) | 1989-10-05 |
| US4999339A (en) | 1991-03-12 |
| EP0422010A1 (en) | 1991-04-17 |
| JPH03503647A (ja) | 1991-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE8402560D0 (sv) | Farmaceutisk komposition | |
| KR900700124A (ko) | 흑색종 치료용 il-2 및 dtic의 치료 조성물 | |
| RU94033520A (ru) | Впрыскиваемый лецитиновый гель | |
| PH24313A (en) | Emulsion composition for administration of sparingly water soluble ionizable hydrophobic drugs | |
| KR960034219A (ko) | 글루카곤-유사형 인슐린 분비 촉진 착체, 조성물 및 방법 | |
| IT8709354A0 (it) | Siringa per iniezioni,in specie endovenose,realizzata per poteressere usata una sola volta,senza possibilita' di riaspirazione. | |
| KR930003912A (ko) | 울혈성 심장 마비 치료법 | |
| ATE188219T1 (de) | Pharmazeutische dipeptid zusammensetzungen und verwendungsmethoden. | |
| PL316942A1 (en) | Novel pharmaceutic compositions based on taxoides | |
| ATE189228T1 (de) | Peptide mit zyklischen hauptketten, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| BG91270A (bg) | Антивирусно и антибактериално средство и метод за използването му | |
| TR200002299T2 (tr) | Epotilon kompozisyonları. | |
| SE9301290D0 (sv) | Anvaendning av en somatostatinanalog | |
| EA200200348A1 (ru) | Фармацевтические растворы левосимендана | |
| ATE104863T1 (de) | Pharmazeutische formulierung von plasminogenaktivatorproteinen. | |
| ATE134294T1 (de) | Zusammensetzung mit psyllium | |
| KR910018038A (ko) | 원발성 흉막암의 치료를 위한 제약 조성물 제조용 인체 인터루킨 2활성 함유 폴리펩티드의 용도 | |
| ATE211765T1 (de) | Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen | |
| IT1204400B (it) | Composizioni farmaceutiche contenente una calcitonina | |
| NO863027L (no) | Peptidpreparater med kontinuerlig avgivelse. | |
| NO20042100L (no) | Fremgangsmate for administrering av et tymosinalfa 1-peptid | |
| GB1514049A (en) | Cross-linked orgotein | |
| KR870010871A (ko) | 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법 | |
| FR2701952B1 (fr) | Nouveaux dérivés cyclopeptidiques de l'angiopeptine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
| KR900701311A (ko) | 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19891124 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |